Know What's Happening in Healthcare
Know What's Happening in Healthcare
Healthcare Pulse
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
EMAIL DIGESTS
Daily
Every morning
Weekly
Tuesday recap
Breakthrough Non‑Hormonal Male Pill Shows 95% Efficacy in Phase‑III Trials
A multinational research team announced a reversible, non‑hormonal male contraceptive pill that achieved 95% efficacy in Phase‑III trials. The compound was safe across a diverse cohort with no hormonal side effects, and participants regained normal fertility within three months after stopping treatment.
Also developing:
By the numbers: Gilead to acquire Tubulis for $5B
Idaho eliminated Medicaid‑funded assertive community treatment (ACT) services for people with severe mental illness, including schizophrenia, in late 2025. Within weeks, several patients lost access to home‑based care and medication management, and at least five deaths were reported, highlighting the program’s critical role. The fatalities, involving individuals from both urban and tribal communities, prompted state legislators to vote to reinstate funding for ACT. The reversal underscores the fragile balance between cost‑cutting and public health safety nets.
In March, the med‑tech sector highlighted three breakthrough programs that attracted venture capital attention. Jiangsu and Shanghai Hengrui patented selective Nav1.8 sodium‑channel blockers and plan IND‑enabling toxicology this year, targeting chronic pain with a Phase I start in 2027. New single‑cell...
On April 7, 2026, BioWorld reported three notable biotech developments. Jiangsu and Shanghai Hengrui patented novel Nav1.8 sodium‑channel blockers, a potential new class for chronic pain management. Researchers highlighted hematopoietic stem‑cell studies that implicate inflammation as an early driver of...
On April 7, 2026 regulators issued several high‑profile decisions across biopharma and medical‑technology. Allevion secured FDA clearance for its next‑generation gene‑therapy platform, Regeneron obtained EMA approval for a monoclonal antibody targeting a rare autoimmune disorder, and Stereotaxis earned a CE...
BioWorld’s April 7 briefing highlights three notable developments: Jiangsu and Shanghai Hengrui have patented a new class of Nav1.8 sodium‑channel blockers aimed at chronic pain treatment; recent hematopoietic stem‑cell research underscores inflammation’s role in initiating leukemia; and Infinimmune presented preclinical data...
BioWorld Asia’s April 7 2026 briefing highlighted three emerging biotech developments. Jiangsu and Shanghai Hengrui patented selective Nav1.8 blockers that deliver strong analgesic effects with minimal off‑target activity, positioning them as potential first‑in‑class chronic pain therapies. New research linked chronic inflammation in...
BioWorld’s April 7 briefing spotlights three notable biotech developments. Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that deliver strong analgesic effects with minimal off‑target activity, opening a potential new class for chronic pain. Parallel studies reveal...
Sononeu, a Boston‑based biotech, secured a $5.2 million grant from the U.S. Advanced Research Projects Agency for Health (ARPA‑H) to advance its ultrasound‑activated therapeutic platform. The award will fund pre‑clinical development of drug‑delivery systems that release payloads only when exposed to...
Amplia Therapeutics announced it is halting enrollment in its phase II trial of the investigational pancreatic cancer agent after an interim safety review revealed concerning signals and modest efficacy. The study, which began enrolling patients in early 2025, was designed to...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented novel Nav1.8 sodium‑channel blockers that selectively target pain signaling, showing strong pre‑clinical analgesic activity with minimal off‑target effects. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, creating a microenvironment that...
BioWorld’s April 7, 2026 clinic roundup compiles a broad set of data snapshots, special reports and infographics spanning biopharma, medical technology, and emerging therapeutic areas. The collection links to analyses on M&A activity, GLP‑1 developments in China, mRNA vaccine research, pulsed‑field ablation...
Jiangsu and Shanghai Hengrui Pharmaceuticals have patented selective Nav1.8 sodium‑channel blockers that show potent analgesic activity with minimal off‑target effects, opening a new avenue for chronic pain treatment. Parallel research highlights how chronic inflammation reshapes hematopoietic stem cells, fostering early...
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without motor side effects, and plan IND‑enabling studies later this year. Parallel research highlights chronic inflammation’s role in reshaping hematopoietic stem cells, fostering leukemic...
A cyberattack on Signature Healthcare Brockton Hospital in Massachusetts forced the facility to turn away ambulances and activate downtime procedures, cancelling chemotherapy infusions while keeping emergency rooms and surgeries operational. The hospital is working with external experts to restore systems,...
Vernacare, backed by private equity firm H.I.G., announced the acquisition of Eakin Surgical, a UK manufacturer of single‑use surgical instruments and procedure solutions. The deal adds a proven line of disposable tools to Vernacare’s existing portfolio, strengthening its foothold in...
Medicare Advantage enrollment, once a growing staple, saw a sharp reversal in 2026 as nearly 3 million seniors were forced to leave their plans. Disenrollment rates surged to 10% of beneficiaries, driven by insurers exiting counties due to rising medical costs...
ARPA-H announced a $100 million program to fund clinical trials for joint regeneration. Three leading academic centers were selected to test innovative therapies aimed at repairing and regrowing damaged cartilage and bone. The projects will explore senolytic drugs, engineered tissue scaffolds,...
Gilead Sciences announced a deal to acquire German biotech Tubulis for $3.15 billion upfront, potentially rising to $5 billion with milestones. The purchase adds a next‑generation antibody‑drug conjugate (ADC) platform and two clinical candidates, TUB‑040 and TUB‑030, to Gilead’s oncology pipeline. This...
Merck agreed to acquire Terns Pharmaceuticals for $6.7 billion, a price roughly 13% lower than its initial offer after new clinical data raised concerns. The renegotiated deal reflects the impact of late‑stage trial results on valuation in the biotech M&A wave....
Recently more than one person called my Health Tech startup @SeamlessMD the “incumbent”. While we’ve been around 13+ years, it feels strange to call ourselves that - probably because we view the EHR as the incumbent. That said, there are...
Novo Nordisk has introduced a high‑dose 7.2 mg version of its obesity drug Wegovy in the United States, expanding the GLP‑1 portfolio beyond the standard 2.4 mg dose. The new formulation targets patients with severe obesity who need greater weight‑loss efficacy. Pricing...
CMS released the Contract Year 2027 Medicare Advantage and Part D final rule, rolling back four health‑equity requirements, removing 11 of 12 STAR measures and adding a depression‑screening metric, and inserting supplemental‑benefit provisions from the prior year’s proposal. The agency also...
Irish engineer Aonghus O’Donovan has launched the MyCelsius cooling bracelet, a wrist‑worn device that drops skin temperature by 10 °C in under ten seconds. The wearable, entering the Irish market on April 7, targets menopausal hot flushes and claims an 80% efficacy...
Researchers demonstrated that enhancing the brain's glymphatic waste‑clearance system can remove a migraine‑triggering chemical in mice, reducing facial pain symptoms. The approach repurposes a hypertension drug to boost clearance, offering a potential therapy for the one‑third of migraine sufferers who...
Jiangsu and Shanghai Hengrui have patented selective Nav1.8 blockers that demonstrate potent pre‑clinical analgesic activity for chronic neuropathic pain. New research links chronic inflammatory signaling to early leukemic transformation in hematopoietic stem cells, suggesting anti‑inflammatory approaches could intervene before disease...
Biopharma financing in 2026 surged to $25.1 billion, almost twice the amount raised in 2025. The jump reflects a wave of venture‑capital commitments, a robust IPO market, and heightened merger‑and‑acquisition activity. Public offerings alone added roughly $8 billion, while private rounds supplied...
Genomic sequencing, a key component of precision oncology, is underused in metastatic cancer care. A JAMA Network Open study of five cancer types found that only about half of patients received tumor genetic testing, with lower rates among low‑income, Medicare/Medicaid,...
Researchers at Jiangsu and Shanghai Hengrui have patented selective Nav1.8 sodium‑channel blockers that alleviate pain in rodent models without cardiac or CNS effects, and plan IND‑enabling toxicology studies in 2026 with Phase I trials slated for 2027. Parallel advances in hematopoietic...
Recent hematopoietic stem cell (HSC) studies reveal that chronic inflammation can seed the earliest genetic lesions that later evolve into leukemia. The research shows that inflammatory signals remodel the bone‑marrow niche, prompting mutations in primitive stem cells long before clinical...
The article examines how India’s Digital Personal Data Protection Act 2023 relies on informed consent to legitimize health data use for AI, but this model struggles with the complex, secondary purposes of AI training. It outlines three consent challenges: multiple...
Hong Kong’s Hospital Authority terminated Dr. Jensen So’s contract after he posted an Instagram story showing a resuscitation procedure in a public ward. The authority said the doctor breached the professional code of conduct, lacked integrity and compromised patient privacy. The...
Gilead announced a deal to acquire German ADC specialist Tubulis for up to $5 bn, with $3.15 bn paid upfront and up to $1.85 bn in milestones. The transaction, slated to close in Q2 2026, brings Tubulis' lead candidate TUB‑040—a NaPi2b‑directed topoisomerase‑I inhibitor in...
The U.S. Food and Drug Administration has granted an investigational device exemption (IDE) for TRiCares' Topaz transcatheter tricuspid valve replacement system, allowing a pivotal randomized trial across the United States, Canada, and Europe. The study will involve up to 75...
The University of Washington expanded its Health Care Alternative Spring Break program to include pre‑med students shadowing emergency medical services at Longview Fire Department. In 2024, 82% of the department’s calls were medical, underscoring the relevance of pre‑hospital experience. Students...
Nearly 2,000 procedures have been guided by virtual-twin modeling, where a dynamic digital replica is used for practice surgery, and it keeps getting better. https://spectrum.ieee.org/living-heart-project-virtual-twins
Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis https://t.co/xEMXvDq2LL by @gwendolynawu $GILD #biotech
Healthcare stocks are gaining momentum as the Centers for Medicare & Medicaid Services signaled higher Medicare Advantage payment rates for 2027. The prospect of increased reimbursements is boosting profit outlooks for managed‑care providers, with CVS Health rallying 4.5% after the...
You don’t always feel cancer in the early stages. Some cancers stay silent until they’re advanced... Your real obligation: pay attention to persistent changes in your body and keep up with proven screenings like mammograms, Pap tests, and colonoscopies.
Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers 🌟This roadmap aims to stimulate advances to accelerate cancer etiology research and prevention in the era of rising early-onset cancers. https://t.co/d0z6EHDpTh https://t.co/H6I76e4tFB
The article argues that healthcare revenue‑cycle partners must shift from reactive "tell us what you need" approaches to proactive, anticipatory support. Operators juggling access, staffing, patient experience, and finances often lack the bandwidth to articulate needs during crises. By identifying...
We should be prioritizing prevention of cancer instead of the major focus on detection and treatment. A new @CellCellPress perspective https://t.co/Gkso3gGPOI
Besides the lack of data for safety or efficacy on peptides, or any assurance of sterility, here's what an independent lab found of samples: —The vial of BPC-157 contained lead —The vial of TB-500 contained endotoxins —The vial of CJC-1295 contained <42% of...
Novo Nordisk launched Wegovy HD, a 7.2 mg semaglutide injection, across the United States. Clinical data from the Phase III Step Up trial showed an average 21% weight loss under ideal conditions and 19% in real‑world adherence, with nearly one‑third achieving ≥25% loss....
The multitude of ways that jack up American healthcare costs (without improving outcomes) @armollica @WSJGraphics @annawmathews gift link https://t.co/FjseZsYQiT https://t.co/QcAmpv2L5r
A new JAMA Psychiatry study shows the antidepressant mirtazapine can modestly reduce methamphetamine use. In the double‑blind Tina Trial, 339 Australian participants received either 30 mg daily mirtazapine or placebo for 12 weeks. Those on mirtazapine cut meth use by an...
TNO155, also known as batoprotafib, is an oral, allosteric SHP2 inhibitor that stabilizes the phosphatase in its inactive conformation. Developed by Novartis in Cambridge, MA, it emerged from a 1.5 million‑compound high‑throughput screen combined with structure‑based drug design, becoming the first...
PharmaForce has named Lynn Eschenbacher, PharmD, MBA, FASHP, as its new Chief Pharmacy and Strategy Officer to steer the company’s 340B program strategy. Eschenbacher brings over 25 years of pharmacy leadership across major health systems, most recently at Quva Pharma. The...
No one becomes a doctor to click boxes on a drop-down menu. By bringing AI-powered documentation directly into Southwest General Health Center’s EHR, we’re turning conversations into structured notes and helping clinicians focus on patient care. https://t.co/1hep681ixQ
Medication non‑adherence still costs U.S. drug makers roughly $250 billion a year, despite billions spent on marketing. Independent pharmacies, which patients visit nearly twice as often as primary‑care doctors, are emerging as a critical touchpoint as chain stores close. New pharmacy‑focused...
Humira, AbbVie’s adalimumab used by over 300,000 Americans, continues to dominate the market even after its patent expired, keeping prices sky‑high. The drug’s outsized share illustrates systemic flaws in U.S. pharmaceutical distribution, where limited biosimilar competition and opaque pricing inflate...
